© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
August 31, 2021
Data show the outcome of all-cause mortality, MI, or stent thrombosis occurred in 5.3% of patients vaccinated against the flu and 7.2% of patients who were given placebo.
Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.
Investigators observed systolic blood pressure was lower by a rate of 6.9 mm Hg in the intervention group versus the control group.
Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.
August 30, 2021
Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.
Data show oral anticoagulation following atrial fibrillation screening was initiated in 1036 participants, with 445 (29.7%) in the ILR group versus 591 (13.1%) in the control group.
Dr. Bhatt discusses the growing field of knowledge surrounding icosapent ethyl treatment in cardiovascular care.
Despite conflicting evidence surrounding older patient populations, investigators found no age-specific treatment effects on major cardiovascular outcomes.
August 29, 2021
Dr. Bhatt discusses a subgroup analysis of the REDUCE-IT to determine if icosapent ethyl reduced further ischemic events in patients with prior MI.
Investigators find that substitute salt better protects older people with a history of stroke or high blood pressure against secondary outcomes of cardiovascular events and death.